Compare ALAR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | BLRX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 11.7M |
| IPO Year | 2018 | 2010 |
| Metric | ALAR | BLRX |
|---|---|---|
| Price | $1.22 | $1.52 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | $16.00 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 30.6K | 10.4K |
| Earning Date | 11-25-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.89 | $37.33 |
| Revenue Next Year | $26.13 | $37.06 |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $1.60 |
| 52 Week High | $14.50 | $3.95 |
| Indicator | ALAR | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 18.16 |
| Support Level | N/A | N/A |
| Resistance Level | $1.59 | $3.04 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 20.00 | 9.78 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.